Strategy overcomes EZH2 inhibitor resistance in SMARCB1 mutated cancer

(Memphis, Tenn.—May 9, 2022) Inhibitors of the protein EZH2 are effective against cancers with SMARCB1 mutations such as rhabdoid tumors in children. However, these drugs are subject to treatment resistance. Scientists at St. Jude Children’s Research Hospital have identified a novel drug target that may help overcome resistance to EZH2 inhibitors. A paper on the work appeared today in Molecular Cell.

 

Rhabdoid tumor is a rare cancer that occurs in children. It can grow in the kidneys and soft tissues (malignant rhabdoid tumor) or in the brain (atypical teratoid rhabdoid tumor). These cancers have a characteristic loss of SMARCB1 (a mutation where the gene and the protein it creates is missing).

 

Previous work by corresponding author of the study Charles W.M. Roberts, M.D., Ph.D., St. Jude Comprehensive Cancer Center director, showed that inhibitors of EZH2 are effective against cancers with SMARCB1 mutations. EZH2 is a component of the Polycomb repressive complex, a multi-protein machine that silences gene expression at specific genes.

 

The EZH2 inhibitor Tazemetostat is U.S. Food and Drug Administration (FDA) approved for cancers with SMARCB1 mutations. Roberts’ work inspired further investigations and then clinical trials of the EZH2 inhibitor Tazemetostat, which ultimately resulted in FDA approval for its use in cancers that carry SMARCB1 mutations.   

 

Resistance, where a cancer cell finds a way to circumvent a drug’s effect, is a common problem that can make therapies ineffective. In the current study, Roberts’ team investigated the mechanisms cancer uses to resist EZH2 inhibitor treatment. The scientists used CRISPR screens in SMARCB1-mutant rhabdoid tumor cells to identify potential resistance mechanisms.

 

“This study illuminates how chromatin regulators interact to control transcription,” Roberts said. “It not only helps us understand this aggressive childhood cancer but also offers insight into treating cancers that carry activating mutations in EZH2.”

 

Chromatin regulation holds the key

 

Chromatin is a complex of DNA and protein tightly compacted inside cells. Chromatin must unwind to turn genes on and off in closely regulated processes. Cancers often carry mutations that affect the SWI/SNF chromatin remodeling complex, of which loss of SMARCB1 is one example.

 

The study showed that loss of the chromatin regulator NSD1 caused EZH2 inhibitor resistance. The researchers showed how NSD1 coordinates transcriptional control and expanded their understanding of the relationship between SWI/SNF and Polycomb. When cancers have a loss of SMARCB1 and are treated with an EZH2 inhibitor, the genes that cause the cell to differentiate are turned back on.

 

“We discovered that NSD1 is that critical next step after EZH2 inhibition to focus on in terms of getting this drug to be effective and understanding how the transcriptional network gets activated,” said first author Yiannis Drosos, Ph.D., St. Jude Oncology Department. “We know NSD1 is doing that by placing a very specific mark on chromatin, so we started thinking how can we get around it?”

 

The researchers found that the cells need NSD1 to turn on the genes that are activated by EZH2 inhibition such that loss of NSD1 results in resistance to EZH2 inhibition. To circumvent the resistance the scientists looked to a gene that opposes NSD1 function. The researchers showed that inhibiting this gene, called KDM2A, restored sensitivity of the cancer cells to EZH2 inhibition.

 

This finding extends beyond rhabdoid tumor to any cancer with a loss of SMARCB1, such as some lymphomas. Currently there is not an inhibitor of KDM2A ready for clinical use, but the findings may support development by a pharmaceutical company in the future.

 

The work was part of the St. Jude Collaborative Research Consortium on Chromatin Regulation in Pediatric Cancer. Through the collaborative, investigators at different institutions conduct research that requires the expertise of scientists with different specialties streamlining and speeding up progress.

 

Authors and funding

The study’s authors are Federica Piccioni and David Root, Broad Institute of MIT and Harvard; Natarajan Bhanu and Benjamin Garcia, University of Pennsylvania; and Jacquelyn Myers, Beisi Zu, Kaeli Mathias, Emma Beane, Sandi Radko-Juettner, Robert Mobley, Margaret Larsen, Xiaotu Ma, Jonathan Low, Baranda Hansen, Samuel Peters, Sandeep Dhanda, Taosheng Chen, Santhosh Upadhyaya, Shondra Pruett-Miller and Janet Partridge of St. Jude.

The study was supported by grants from the National Cancer Institute (R01CA113794, R01CA172152, R01CA196539, CCSG2P30CA021765, and F31CA261150); CURE AT/RT Now, Garret B. Smith Foundation, and ALSAC, the fundraising and awareness organization of St. Jude.

St. Jude Media Relations Contacts

 

Michael Sheffield
Desk: (901) 595-0221
Cell: (901) 275-9065
[email protected]
[email protected]

 

Emily Gest 

Desk: (901) 595-0260 

Cell: (901) 568-9869 

[email protected] 

[email protected] 

 

St. Jude Children’s Research Hospital

St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.”

---

---